Hardman Johnston Global Advisors LLC lowered its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,580 shares of the specialty pharmaceutical company’s stock after selling 610 shares during the period. Hardman Johnston Global Advisors LLC owned about 0.07% of Jazz Pharmaceuticals PLC worth $6,374,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. raised its position in Jazz Pharmaceuticals PLC by 41.2% during the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock worth $218,540,000 after acquiring an additional 410,031 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new position in Jazz Pharmaceuticals PLC during the second quarter worth about $10,108,000. HighTower Advisors LLC acquired a new position in Jazz Pharmaceuticals PLC during the first quarter worth about $347,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Jazz Pharmaceuticals PLC by 13.8% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 17,469 shares of the specialty pharmaceutical company’s stock worth $2,716,000 after acquiring an additional 2,121 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Jazz Pharmaceuticals PLC by 11,990.7% during the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock worth $135,894,000 after acquiring an additional 866,691 shares during the last quarter. Institutional investors own 88.55% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same quarter last year, the business earned $2.67 EPS. The company’s revenue for the quarter was up 3.5% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: “Hardman Johnston Global Advisors LLC Cuts Holdings in Jazz Pharmaceuticals PLC (JAZZ)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/hardman-johnston-global-advisors-llc-cuts-holdings-in-jazz-pharmaceuticals-plc-jazz/1673658.html.

In other news, Director Paul L. Berns sold 662 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $142.37, for a total value of $94,248.94. Following the sale, the director now owns 6,599 shares in the company, valued at $939,499.63. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Paul Treacy sold 1,304 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $143.32, for a total transaction of $186,889.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,517 shares of company stock worth $665,623. Corporate insiders own 4.30% of the company’s stock.

A number of equities analysts have issued reports on the stock. Wells Fargo & Company restated an “outperform” rating and set a $177.00 target price (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Cowen and Company restated an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Piper Jaffray Companies reissued a “buy” rating and issued a $177.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Janney Montgomery Scott reissued a “buy” rating and issued a $192.00 price objective (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $196.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $180.88.

Jazz Pharmaceuticals PLC Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.